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Abstract
Aims: Aging is among the major causes for the lack of cardiovascular protection by estrogen (E2) during postmenopause.
Our study aims to determine the mechanisms whereby aging changes E2 effects on nitric oxide (NO) production in a mouse
model of accelerated senescence (SAM).
Methods and Results: Although we found no differences on NO production in females SAM prone (SAMP, aged) compared
to SAM resistant (SAMR, young), by either DAF-2 fluorescence or plasmatic nitrite/nitrate (NO2/NO3), in both cases, E2
treatment increased NO production in SAMR but had no effect in SAMP. Those results are in agreement with changes of
eNOS protein and gene expression. E2 up-regulated eNOS expression in SAMR but not in SAMP. E2 is also known to increase
NO by decreasing its catabolism by superoxide anion (O2
-). Interestingly, E2 treatment decreased O2
2 production in young
females, while increased O2
2 in aged ones. Furthermore, we observed that aging changed expression ratio of estrogen
receptors (ERb/ERa) and levels of DNA methylation. Increased ratio ERb/ERa in aged females is associated to a lack of
estrogen modulation of NO production and with a reversal in its antioxidant effect to a pro-oxidant profile.
Conclusions: Together, our data suggest that aging has detrimental effects on E2-mediated benefits on NO bioavailability,
partially by affecting the ability of E2 to induce up regulation of eNOS and decrease of O2
2. These modifications may be
associated to aging-mediated modifications on global DNA methylation status, but not to a specific methylation at
59flanking region of ERa gene.
Citation: Novensa ` L, Novella S, Medina P, Segarra G, Castillo N, et al. (2011) Aging Negatively Affects Estrogens-Mediated Effects on Nitric Oxide Bioavailability by
Shifting ERa/ERb Balance in Female Mice. PLoS ONE 6(9): e25335. doi:10.1371/journal.pone.0025335
Editor: Consuelo Borras, University of Valencia, Spain
Received June 26, 2011; Accepted September 1, 2011; Published September 22, 2011
Copyright:  2011 Novensa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Spanish Grant from Ministerio de Ciencia e Innovacio ´n, Instituto de Salud Carlos III (grants FIS PI1000518, FIS PI080176
and Red HERACLES RD06/0009), and Consellerı ´a de Sanidad (grants AP-131/10, AP-117/10, and GE-021/10). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: adantas@clinic.ub.es
Introduction
The surprising controversies on the risk-benefits of estrogen
replacement therapy (ERT) may, in part, be explained by age
disparity among studies. While the cardiovascular effects of
estrogen in experimental studies have been determined mostly in
young ovariectomized females, clinical trials have been carried out
on aged women, who were on average, 10 years past the onset of
menopause[1,2]. Aging, per se, is known to cause a series of
alterations in the endogenous mechanisms that control cardiovas-
cular function leading to subsequently increased risk of cardio-
vascular disease[3,4,5]. Detailed examination of the data from the
Woman’s Health Initiative (WHI) indicates that early initiation of
estrogen replacement produces more favorable results than the
late average time of initiation employed in the WHI studies overall
[6,7,8]. These observations together with other observational
studies have led scientists to create the so-called ‘‘Timing
Hypothesis’’. This theory states that estrogen-mediated benefits
to prevent cardiovascular disease may occur only when treatment
is initiated before the detrimental effects of aging on cardiovas-
cular disease are established in the vasculature[9].
Since this is a relatively recent theory, little information is
available on whether and how vascular effects of estrogen are
modified with aging in females. Few studies have shown that aging
in female rodents is associated with significant reduction of
estrogen-mediated cardiovascular effects. The lack of estrogen
responses in those animals was not related to age-associated
changes in the plasma levels of estrogen or activity of estrogen
receptors, but rather by possible age-related changes in estrogen-
mediated signaling pathways in the vasculature[10,11,12]. More-
over, recent clinical studies have revealed that different risk factors
for cardiovascular disease in postmenopausal women were lower
among women 50 to 59 years old at enrollment for ERT[13,14].
These studies demonstrate that estrogen has complex biologic
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other outcomes through multiple pathways. Nevertheless, the field
lacks detailed research on the long-term effects by estrogen and
how it modulates cardiovascular function during aging. It remains
unclear to what extent the protective effects of estrogen
replacement well described in young females can be extrapolated
to older ones. Cardiovascular disease is the number one killer of
women in the Western world. Thus, it is imperative we understand
the mechanisms underlying why the vast number of experimental
studies indicate estrogen replacement is cardioprotective while no
beneficial effect was observed in clinical trials such as the WHI. To
address this important issue, this study aims to determine how
aging can affects nitric oxide production by estrogen in female
vasculature.
Methods
Female senescence-accelerated resistant (SAMR, young) and
senescence-accelerated prone (SAMP, aged) mice obtained from
the breeding stock at Parc Cientific de Barcelona were housed at
Animal Facility of University of Barcelona according to institu-
tional guidelines (constant room temperature — 22uC, 12 h light/
dark cycle, 60% humidity, standard mice chow and water ad
libitum). All protocols were approved by the Institutional Ethics
Committee at the University of Barcelona (Comite `E `tic d’Experi-
mentacio ´ Animal – CEEA protocol: 625/08), conformed to the
National Institute of Health Guide for the Care and Use of
Laboratory Animals. SAM model was chosen based on previous
studies from our group establishing SAMP-OVX as a good model
to concomitantly study the effects of aging and menopause in
middle-aged female mice [15]. Both SAMR (n=40) and SAMP
(n=45) were randomly separated at 7 months of age into two
groups: 1) ovariectomized (OVX); and 2) ovariectomized chron-
ically-treated with estrogen (OVX+E2). This age was chosen based
on preliminary studies to determine the beginning of vascular
senescence in SAMP, but not in SAMR[15,16]. Ovariectomy was
performed under controlled inhalant anesthesia with isoflurane
(4% induction and 1.5–2% maintenance). After ovariectomy, mice
were treated either with vehicle or 17b-estradiol in mineral oil
solution (5 mg/kg) by subcutaneous injection every three days in
order to simulate the estral cycle[17]. The efficacy of ovariectomy
and estrogen treatment was determined by uterine weight. Four
weeks following ovaricetomy, all mice were euthanized by
anesthesia with isoflurane and aorta was harvested from the aortic
arch to the common iliac artery. In order to establish a correlation
among results, in a set of animals half of the aorta was gradually
frozen in Tissue-TekH OCT compound (for protocols in aortic
section), and the other half was snap frozen into liquid nitrogen
(for mRNA and DNA analysis).
Nitric Oxide Measurements
Because of its short half-life, NO production was determined by
both intracellular nitrosilation of NO-sensitive fluorochrome DAF-
2 in aortic sections and by measuring the concentration of NO
metabolites nitrite (NO2) and nitrate (NO3) in plasma. For DAF-2,
aortic sections (4 mm) were incubated with a permeable form
DAF-2 DA (5 mM, 30 min, 37uC) and kept in the dark at 37uC
with a warming stage on an inverted confocal microscope
(Axiovert 2000, Carl Zeiss Inc). DAF-2 fluorescence was assessed
basally at excitation/emission wavelength of 495/515 and after
challenging with carbachol (10 nM to 100 mM) to increase NO
production, with readings taken 5 min after exposure to the
agonist. Images were recorded by Axiovision 4.6 software (Zeiss
Imaging) and increase of green fluorescence intensity by the
distinct groups of animals was measured with Mac Biophotonic
ImageJ Software. Data were expressed as fold increase following
carbachol stimulation. The levels of NO metabolites (NO2/NO3)
were determined in the plasma by a commercial colorimetric assay
kit (Cayman Chemical Company) following the supplier’s
instructions.
NAD(P)H oxidase Activity
Lucigenin-enhanced chemiluminescence was used to determine
superoxide production after adding excess NADPH (100 mM), the
substrate for NAD(P)H oxidase, as described [18]. This method is
specifically designed to measure NAD(P)H oxidase capacity.
Freshly isolated aortas were placed into distinct centrifuge tubes
containing Krebs-Henseleit solution with lucigenin (5 mM) and
kept at 37uC. Increase of luminescent signal following addition of
100 mM NADPH was determined in a luminometer (Berthold
AutoLumat Plus) every 2 seconds for a 3-minute period.
Background counts (determined in tissue-free preparations) were
subtracted from images, and values were normalized to protein
content (BCA assay).
Immunofluorescence
Protein expression and localization of eNOS and ERs (ERa and
ERb) were determined in aortic sections from SAMR and SAMP
mice by immunofluorescence as previously described[15]. Aortic
sections (4 mm) were thaw-mounted onto polylysine covered slides,
fixed in acetone (15 min) and blocked for 30 min with horse
serum. Sections were incubated overnight at 4uC with primary
antibodies: 1:200 anti-eNOS (Abcam - ab5589), 1:100 anti-ERa
(Abcam - ab37438) or 1:50 anti-ERb (Abcam - ab3576). Following
washes, sections were co-stained with 10 mM phalloidin (Sigma)
and secondary antibodies 1:500 Alexa Fluor 488 conjugated goat
anti-rabbit (Invitrogen) for eNOS or 1:500 Alexa Fluor 647
conjugated donkey anti-rabbit (Invitrogen) for ERs. Coverslips
were mounted on slides using ProLong Gold antifade reagent with
DAPI (Invitrogen), and sections were visualized through a confocal
microscope (Axiovert 2000, Carl Zeiss Inc) with a 40X objective
lens (Zeiss). For each image, light was passed through a different
excitation filter: 1) 350 nm (for DAPI); 2) 490 nm (for Alexa 488);
3) 590 nm (for phalloidin) and 4) 650 nm (for Alexa 647). Each
aorta was recorded in 3 different regions and results were
expressed as an average of fluorescence elicited using Mac
Biophotonic ImageJ Software.
Western blot analysis
Equal amount of protein from each sample (50 mg) were
resolved by SDS-PAGE on 4-12% gels and electroblotted onto
nitrocellulose. After 1 h blocking with 5% milk in Phosphate-
buffered saline with 0.1% (v/v) Tween 20 (PBST), membranes
were incubated for 1 h in PBST containing 5% milk and the
specified primary antibody: monoclonal anti eNOS, 1:1000 (BD
Transduction Laboratories). After 4 washes with PBST, mem-
branes were incubated for 1 h with a horseradish peroxidase-
labeled goat anti-mouse at a 1:2000 dilution in PBST containing
1% milk. After 4 additional washes in, the membranes were
incubated with a chemiluminescent reagent according to the
manufacturer’s protocols (SuperSignal west pico, Pierce Chemical
Co), and chemoluminescent signal was visualized by LAS3000
imaging system (Fujifilm). Densitometric analyses of Western blots
were performed using a Mac Biophotonic ImageJ Software. All
membranes were reblotted using a monoclonal antibody anti
GAPDH (1:2500; Santa Cruz Biotechnology) as a loading control.
Data were normalized to corresponding values of GAPDH
densitometry.
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Total RNA was isolated and reverse transcribed as previously
described [19]. mRNAs encoding eNOS, the subunities of
NAD(P)H-oxidase (NOX1, p47
phox, p22
phox) and ER (ERa,
ERb) were quantified by qRT-PCR based on SYBRH Green
fluorescence, using the 18S ribosomal subunit of RNA (Invento-
ried: Hs99999901 s1, Applied Biosystems) as internal control. The
specific primer sequences for mice are described on Table 1. Real-
time PCR reactions were set following the manufacture’s con-
ditions (Applied Biosystems).
Analysis of Global Methylation
Global DNA methylation status was determined by non-isotopic
cytosine extension assay, as previously described[20]. Briefly,
equal amounts of genomic DNA (500 ng), isolated from total aorta
underwent no digestion (Mock) or digestion with 10 U of
methylation-sensitive restriction enzyme HpaII or its isoschizomer
MspI (New England Biolabs) for 16–18 hours in separate tubes.
Digested DNA was subjected to single-nucleotide extension
reaction in a 20 ml reaction containing Taq polymerase (Promega)
and 5 ml of 0.4 mM biotin-14-dCTP (Invitrogen) for 1 h at 56uC.
2 ml in triplicate of each sample were applied on a nylon
membrane for DNA incorporation. After washing with 0.4 N
NaOH and cross-link at U.V. light, biotin incorporated to the
membranes was visualized with HRP-streptavidin reaction
(Pierce), according to manufacturer. Values were corrected for
non specific incorporation by measuring the incorporation of
biotin-dCTP into undigested genomic DNA (Mock samples). The
difference in the mean incorporation of biotin-dCTP following
MspI and HpaII was computed as the global DNA methylation
level and expressed as % of DNA methylation.
Methylation Sensitive qRT-PCR
The methylation status of 59 flanking region of the gene
encoding ERa was determined by methylation specific qPCR, as
described [21]. Following mock digestion or enzymatic digestion
with HpaII or MspI, resulting DNA was amplified using qPCR
with Power SYBRH Green master mix as described by the
manufacturer (Applied Biosystems). PCR primers were designed
using Methyl Primer Software (Applied Biosystems) to amplify the
CpG island that spans the 59 flanking region of ERa gene (MSP)
or to amplify a region that is devoid of any of the restriction sites of
the enzymes used in the design of the experiment (No MSP), as
internal control (Table 1). Methylation at CpG sites prevents
HpaII, but not MspI, digestion and allows the amplification of the
fragment, resulting in a low cycle threshold (Ct) value. In contrast,
if the CpG island is not methylated, HpaII cleaves DNA and
prevent amplification of the fragment, resulting in higher Ct
values. Each sample was analyzed in duplicate.
Data Analysis
Data are expressed as means 6 SEM obtained from 6–8
individual aortic samples from each animal group. Differences
between mouse strains (i.e SAMR vs. SAMP) and by experimental
treatment groups (i.e., OVX vs. OVX+E2) were analyzed by two-
way ANOVA, followed by Bonferroni’s post-test to compare
replicate means. Association between increase of ERb/ERa ratio
and changes on NO production and NOX1 expression in SAMR
and SAMP animals was calculated by Pearson’s Correlation
Coefficient (r). Statistical significance was accepted at p,0.05.
Statistical analysis and Pearson’s Coefficient calculation were
carried out using Graph Pad Prism v5 software (GraphPad
Software Inc., San Diego, CA, USA).
Results
We observed important differences on estrogen-mediated effects
on NO production between young (SAMR) and aged (SAMP)
mice. NO production was not significantly modified by aging in
the absence of estrogen in both methods of DAF-2 (Max Fold
Increase: SAMR 1.460.07 vs. SAMP 1.260.04; p=ns) and NO2/
NO3 (mM: SAMR 13.160.8 vs. SAMP 13.561.7 p=ns).
However, treatment with estrogen was effective to increase NO
production only in younger females. A similar pattern of estrogen-
induced increase of NO was observed in aorta (33.7%) and in
plasma (28.3%) of SAMR OVX, whereas no effect was observed
in aged (SAMP) OVX (Figure 1). It is known that the major
mechanism involved on estrogen-induced increase in NO
availability includes transcriptional modulation of eNOS expres-
sion. Therefore, aging-associated decrease of estrogen effect may
be, in part, associated to a diminished action on the modulation of
nitric oxide synthase (eNOS) expression.Both immunofluoresce
(Figure 2A) and Western blot (Figure 2B) analysis reveal that
estrogen treatment is able to increase eNOS protein expression in
aortas of SAMR, but not of SAMP OVX. Those results are in
agreement with results from mRNA expression (Figure 2C)
showing that estrogen treatment is effective to modulate eNOS
gene expression only in SAMR females. In addition, the decreased
estrogen-mediated modulation of NO in aged females could be
explained by a change on NO catabolism. The biological activity
of NO is modulated by changes in reactive oxygen species (ROS),
such as superoxide anion (O2
2) [22]. Because estrogen has been
described to increase NO by an antioxidant mechanism that
involves down-regulation of NAD(P)H oxidase, we have also
explored the potential role of aging on estrogen-induced
modulation of NAD(P)H oxidase activity and expression. In
preliminary studies, lucigenin-luminescence was determined in the
presence of apocynin (10 mM) and by using xanthine(100 mM) as
a substrate. In both cases the superoxide-induced increase in
luminescence was blunted, confirming that NADPH-oxidase is the
major source for superoxide generation in aorta from SAM mice
(data not shown). Curiously, although we have observed in
previous studies that aging per se markedly increases oxidative stress
in our mice model, we found in these studies that estrogen plays a
Table 1. Primers designed for qPCR experiments.
Gene Sequence(59R39)
eNOS (NM_008713.4) F: TGTCACTATGGCAACCAGCGT
R: GCGCAATGTGAGTCCGAAAA
NOX1 (NM_172203.1) F: CCTTCCATAAGCTGGTGGCAT
R: GCCATGGATCCCTAAGCAGAT
p22
phox (NM_007806.3) F: GGCCATTGCCAGTGTGATCTA
R: TGCTTGATGGTGCCTCCAA
p47
phox (NM_010876.3) F: AGGAGATGTTCCCCATTGAGG
R: CAGTCCCATGAGGCTGTTGAA
ERa (NM_007956.4) F: TGCCTGGCTGGAGATTCTG
R: CTTCCCCGGGTGTTCCAT
ERb (NM_207707.1) F: CAGGCTGAGCGACAACCA
R: CTCTAAATGCAGACACGTACTTTCCT
ERa 59 flanking region (MSP)
(AJ276597.1)
F: GTTAAGGGGAATTATGCGTGC
R: TTACAAACTAACTCCCCGCG
ERa 59 flanking region (No MSP)
(AJ276597.1)
F: GTGTTAAGGGGAATTATGTGTGT
R: TTACAAACTAACTCCCCACACA
doi:10.1371/journal.pone.0025335.t001
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2 modulation. As can be seen on Figure 3A,
young OVX exhibits a much higher NAD(P)H oxidase-associated
superoxide generation than do aged females (AUC: SAMR
40596613680 vs. SAMP 1015362357, p,0.05). Furthermore,
and even more intriguing is the finding that estrogen treatment
acts as an antioxidant in young females while has pro-oxidant
effects in old females (Figure 3A). These responses can be
associated to a reversal of estrogen-mediated action on the
expression of NAD(P)H oxidase subunities, as we have observed
that estrogen has opposite effects on the modulation of NOX1
subunit in SAMR OVX in comparison to SAMP OVX
(Figure 3B). We observed that aged OVX expresses much lower
levels of NOX1 than do young ones (mRNA 2
2DCt: SAMR
1.5610
2566.1610
26 vs. SAMP 5.3610
2662.1610
26;p ,0.05),
even though no aging-associated differences were observed on the
expression of p22
phox and p47
phoxsubunits. Estrogen treatment of
Figure 1. NO production in young (SAMR) and aged (SAMP) female mice. (A) representative images of DAF2-DA fluorescence in mice aorta
at basal level and after challenging with carbachol (Cb) 10 mM; (B) dose response, shown as relative green fluorescence intensity (fold increase)
following carbachol stimulation; (C) nitrite/nitrate (NO2/NO3) concentration (mM) in plasma from SAMR and SAMP mice. OVX, ovariectomized;
OVX+E2, ovariectomized treated with estrogen. Data are plotted as the mean 6 S.E.M derived from 6–8 independent experiments. * p,0.05.
doi:10.1371/journal.pone.0025335.g001
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(8.0610
2765.5610
27;p ,0.05), but increased NOX1 expression
in SAMP OVX to the levels observed in untreated SAMR OVX
(1.4610
2563.6610
26;p ,0.05). Although a trend of decrease on
the expression of p22
phox and p47
phox was observed in both
estrogen-treated groups, no statistical significances were found
(Figure 3B), suggesting that NOX1 is the major responsible for the
responses on superoxide generation observed herein.
Most of the vascular protective effects induced by estrogens are
mediated by a direct genomic action through interaction with its
receptors: ERa and ERb. We next explored a potential role of
aging-associated change on the expression of ERs and its potential
correlation with the altered responses on NO/O2
2 production.
On Figure 4 we show the results of immunofluorescence analysis
that determined the expression of ERa and ERb on the
endothelium and smooth muscle cells from SAMR and SAMP
Figure 2. eNOS expression in thoracic aorta from SAMR and SAMP mice. (A) top: representative immunofluorescent merged images.
Staining shows nucleus (blue, DAPI), actin fibers (red, phalloidin), eNOS (green). Bar graphs (bottom) show the results of densitometric analyses from
pooled data. (B) Immunoblots analysis (top) in single aortas probed with antibodies against eNOS or GAPDH, as indicated. The lower graph shows the
results of densitometric analyses from pooled data, plotted as optical densitometry relative to the signal obtained in by GAPDH. (C) eNOS mRNA
expression in mice aorta normalized to the expression of ribosomal RNA subunit 18S, which was used as an endogenous reference gene. OVX,
ovariectomized; OVX+E2, ovariectomized treated with estrogen. Each data represents the mean 6 SEM derived from 6–8 independent experiments.
*p ,0.05.
doi:10.1371/journal.pone.0025335.g002
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expressed in mice aorta (Figures 4B and 4C), and it is present at
higher level at the endothelium in comparison to the smooth
muscle layer (Figure 4B). Aging per se notably alters ERs expression
in both vascular endothelium and smooth muscle in aortas from
OVX mice, as expressed by increased ratio of ERb/ERa
(Figure 4D). Although no statistical significance was found on
ERb/ERa ratio in OVX mice, SAMP OVX shows a marked
Figure 3. NAD(P)H-dependent O2
- production in aorta from young (SAMR) and aged (SAMP) females. (A) On top: Representative
chemiluminescence tracing of NADPH-dependent O2
2production in SAMR and SAMP mice. On the bottom bar graphs represent mean 6 SEM of the
areas under the curve obtained from 6–8 individual experiments. (B) mRNA expression of the NAD(P)H oxidase subunits in mice aorta normalized to
the expression of ribosomal RNA subunit 18S, used as an endogenous control. OVX, ovariectomized; OVX+E2, ovariectomized treated with estrogen.
Each data represents the mean 6 SEM derived from 6–8 independent experiments. * p,0.05.
doi:10.1371/journal.pone.0025335.g003
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merged images shows nucleus (blue, DAPI), actin fibers (red, phalloidin), ER (green: not merged with nucleus or purple: merged with nucleus). Bar
graphs show the results of densitometric analyses from pooled data for ERa (B) and ERb (C) expression in both vascular endothelium and smooth
muscle. (D) Ratio of ERb/ERa expression in both endothelium and vascular smooth muscle. OVX, ovariectomized; OVX+E2, ovariectomized treated
with estrogen. Each data represents the mean 6 SEM derived from 6–8 independent experiments. ** p,0.01 and *** p,0.001.
doi:10.1371/journal.pone.0025335.g004
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endothelium and smooth muscle. Estrogen treatment decreases
ERa expression in both SAMR and SAMP females, but has no
effect on ERb. The magnitude of reduction on ERa after
treatment with estrogen in SAMR is more than that in SAMP,
and is reflected by a significant increase of ERb/ERa in aged,
but not in young females (Figure 4C). Besides, the changes on
ERb/ERa ratio observed on aortic smooth muscle are exceed-
ingly higher than that found on endothelium (Figure 4C).
Comparable results on mRNA expression for ERs were found
on by qRT-PCR (Figure 5A). These studies confirm that ERa is
expressed at much higher level than ERb in mice aorta, and show
that both aging and estrogen down regulates ERa by negatively
modulating its transcription. Interestingly, although ERb mRNA
expression was also augmented in aged groups, the magnitude of
increase on mRNA was much higher (Figure 5A) than that
observed for protein expression (Figure 4C). Furthermore,
Pierson’s Correlation analysis reveals no linear relationship
between changes in ERb/ERa ratio and nitric oxide production
(Table 2). In contrast, a significant positive correlation is seen
between ERb/ERa ratio and NOX1 expression in SAMP
females (Table 2). These data establishes that the marked
increase of ERb/ERa in SAMP OVX+E2 is responsible for
the increased oxidative stress observed.
Figure 5. Aging-associated change on ER expression and DNA methylation. (A) mRNA expression for ERa and ERb in mice aorta normalized
to the 18S expression. (B) Image on top shows a representative experiment of biotin-dCTP incorporation to DNA following no digestion (Mock) and
digestion with MspI (no methylation sensitive) or HpaII (methylation sensitive).DNA was spotted in a nylon membrane and visualized with
streptavidin-HRP method (data shown in triplicate). Bar graphs show (left) the results of densitometric analyses from pooled data for global DNA
methylation and (right) percentage of specific DNA methylation at 59 flanking region of the gene encoding ERa. OVX, ovariectomized; OVX+E2,
ovariectomized treated with estrogen. Each data represents the mean 6 SEM derived from 6–8 independent experiments. * p,0.05; ** p,0.01 and
*** p,0.001.
doi:10.1371/journal.pone.0025335.g005
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been associated to the decrease of gene expression and protein
activity [23]. To test this hypothesis, we evaluated alteration in
global DNA methylation density within CpG islands and in
specific CpG islands on 59 flanking region of ERa. In these studies,
we found that both aging and estrogen treatment affects the levels
of global methylation in female mice. An increase on percentage of
global DNA methylation was observed in SAMP OVX in
comparison to SAMR OVX. Estrogen treatment similarly
enhanced the levels of DNA methylation in SAMR OVX,
although no further increase on DNA methylation was observed
in SAMP OVX (Figure 5B). Studies by methylation-sensitive
qPCR showed increased percentage on DNA methylation at 59
flanking region of the gene encoding ERa in OVX treated mice
from both SAMR and SAMP groups (Figure 5B). No differences
on ERa DNA methylation were observed when SAMR vs. SAMP
were compared.
Discussion
In this study we investigated the hypothesis that aging has a
detrimental effect on the modulatory role of estrogen to regulate
nitric oxide bioavailability in female aorta. To date, few studies
have addressed to the effects of aging on estrogen responses using
rodent models at advanced age. Aging has shown to modify
estrogen-mediated benefits on vascular function in middle aged
female rats with risk for cardiovascular disease[24,25]. On the
other hand, in female rodents that normally do not exhibit
cardiovascular complications, aging-associated changes in vascular
function and estrogen effects are evident only when animals are
senile[11,12,26]. The fact that those studies used animal models
normally display increased risk for cardiovascular disease at early
stage or used senile females, they may not represent the
modifications that are associated with aging and menopause in
women.
In previous studies we have established ovariectomized
senescent accelerated prone (SAMP OVX) mice as a fine model
to study progressive cardiovascular aging in females concomitantly
with loss of ovarian function. At age of six months (middle age)
SAMP OVX exhibits a significant decrease of endothelium-
dependent and NO-mediated relaxation [15]. The fact that those
effects were not as evident on senescent accelerated resistant mice
(SAMR OVX), suggests an overlap between aging and hormonal
status to control endothelial function, that closely mimics vascular
dysfunction observed in menopausal women[27,28]. In view of the
fact that SAMP OVX at 6 months is characterized as middle aged
female that have not reached a high level of vascular damage, we
have found that estrogen treatment is still effective to improve
endothelium-dependent relaxation[16]. In these studies we sought
to determine if the progression of age affects estrogen-mediated
responses on the modulation of nitric oxide. For that, we used our
model of menopause (SAMP OVX) at 7–8 months of age
following immediate replacement with 17b-estradiol or placebo.
We carefully considered the use of an intact control but our
preliminary studies showed that, like other rodents, SAM mice do
not reach reproductive senescence until later in life [29]. At 6–8
months SAMR and SAMP exhibit similar hormonal status with
sustained estrus and slowly declining levels of estrogens [15,29],
and therefore the addition of these multiple groups would
complicate analysis and make it more difficult to discern the
effect of aging on E2 effects, which was the main question of
interest.
A correlation of aging and decrease of endothelium-dependent
and nitric oxide-mediated has been extensively described in both
man and women[14,30], however limited information is available
on the effects of aging on estrogen-mediated action. We found that
aging (at this point) significantly affects estrogen-mediated
mechanisms that modulate nitric oxide bioavailability. While
young females SAMR OVX shows estrogen benefits by up-
regulation of eNOS expression and decrease of oxidative stress, an
interesting reversal in the estrogen effects was observed in older
females. In SAMP OVX estrogen loses its ability to modulate
eNOS expression while significantly increases the expression of
NOX1 and consequent production of superoxide (O2
2). The fact
that aged females (SAMP OVX) received immediate E2
replacement suggests that aging, rather than a long term estrogen
withdrawn is responsible for the lack of estrogen-mediated effects
observed. In agreement with our data, few studies have described
loss of NO modulation by estrogen with aging [10]. However, this
is the first study to describe a swap from antioxidant to pro-oxidant
action by estrogen in association with vascular aging.
Most of estrogen action is mediated by two subtypes of estrogen
receptors (ERa and ERb). Although ERa has been described to be
the receptor responsible for cardiovascular protection, insufficient
and controversial information is available on the contribution of
ERb to the cardiovascular system[31]. Activation of ERa has been
largely associated with increased eNOS transcription and NO
production [19,32], as well as its antioxidant mechanism [33,34].
Studies on ER knockout (ERKO) mice have provided valuable
clues into the tissue-specific roles of these receptors in cardiovas-
cular physiology and pathophysiology. aERKO mouse have
confirmed the importance of ERa in regulating endothelial NO
synthesis. [35,36]. On the other hand, mice lacking functional
ERb develop hypertension despite its normal NO production,
suggesting that ERa is the main ER subtype responsible for NO
production by estrogen[36]. Moreover, increased levels of ERb
Table 2. Pierson Correlation Coefficients between ERb/ERa ration and changes in NO or O2
2 systems.
SAMR SAMP
Pierson r P value Significance Pierson r P value Significance
NO (DAF2) 0.434 0.062 ns 0.383 0.128 ns
eNOS IF 0.513 0.087 ns 20.221 0.410 ns
eNOS mRNA 0.473 0.102 ns 20.151 0.575 ns
Endo (ERb/ERa)
vs NOX1 mRNA
0.409 0.239 ns 0.938 ,0.001 ***
SMC (ERb/ERa)
vs NOX1 mRNA
0.407 0.243 ns 0.951 ,0.001 ***
doi:10.1371/journal.pone.0025335.t002
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calcification and atherosclerosis[31].
While much research focuses on ER-mediated NO production
in the cardiovascular system, few studies have addressed the role of
aging on ER balance and its correlation with estrogen-mediated
effects. In this study we have hypothesized that a change on the
balance of ERa and ERb could account for the lack of vascular
protection by estrogen. In our studies on ER protein expression
and localization, when each ER subtype was individually
correlated with the effects observed on NO and O2
2 production
a quite complex and confusing association can be made. However
an important correlation between changes on the ratio ERb/ERa
and the regulation of NO and O2
2 by aging was found. In our
studies we have observed that aging itself did not affect ERb/ERa
in OVX animals, but markedly alters estrogen-mediated effects on
ERs ratio. In young animals (SAMR OVX), although estrogen
treatment produces a significant down-regulation of ER, it does
not alter ERb/ERa in both endothelium and vascular smooth
muscle. The maintenance of ERb/ERa is associated to beneficial
effects by estrogen, i.e. up-regulation of NO production and
decreased NAD(P)H oxidase activity and NOX1 expression. In
contrast, aged females (SAMP OVX) exhibited a marked increase
of ERb/ERa following estrogen treatment, an effect that positively
correlates to the reversal of beneficial action by estrogen on NO/
O2
2 balance. Corroborating our findings, a recent study have
shown in prostate cancer that the action of estrogen on oxidative
stress and the expression of antioxidant enzymes is dual and
dependent on the ERa/ERb ratio[37].
The mechanisms to explain how the imbalance of ER ratio
reverses estrogen effects are largely unknown, but recent studies
have interestingly revealed that ERb exhibits an inhibitory action
on ERa-dependent gene expression and may oppose the actions of
ERa [38]. Moreover, a study by Bhavnani et al [39] has described
different pattern of transcriptional activity by estrogens when using
distinct ratios of ERa and ERb in cells. Their results show that
increasing ERb concentration 2 or 10-fold inhibited the ERa
activity progressively to levels that were 32 and 34% lower than
those seen when ERa/ERb ratio was 1:1, indicating that the
transcriptional activity of ERa is not only dependent on the
concentration of estrogen, but also on concentrations of ERa/
ERb in a specific cell[39]. Although our data thus far is fairly
descriptive, they provide an important hint on the relevance of
ERa/ERb equilibrium for estrogen-mediated effects on NO
production and oxidative stress. More detailed and sophisticated
protocols in biochemistry and molecular biology are needed to
better characterize the specific role of different amounts of ERa
and ERb on the pharmacology of estrogens to regulate NO and
O2
2 production.
One process that has been increasingly proposed to link aging
and the lack of cardiovascular protection is epigenetic modifica-
tions by vascular senescence [40]. Studies have suggested that
aging-dependent increase in the methylation status of the
promoter region of several genes that encode important regulators
of cardiovascular function could be associated to the progression of
cardiovascular disease, including atherosclerosis [40]. In this
research, we further aimed to determine the occurrence and
pathophysiological implications of aging-associated epigenetic
alterations globally and in the promoter region of the gene that
encodes ERa. Our data show a significant aging- associated
increase on the percentage of global methylation in mice aorta.
Surprisingly, we have also observed that estrogen also contribute
to increase of DNA methylation in mice aorta, even though this
effect cannot be associated to the changes observed herein. DNA
methylation at 59 flanking region of genes has been described as an
important regulator of transcription, and a large body of evidence
has demonstrated that increased DNA methylation is associated
with decreased gene expression and even gene silencing [23].
Furthermore, an increased degree of ERa gene methylation
appears to be associated to coronary atherosclerotic plaques and to
vascular cell senescence [41]. Based on these principles, we have
explored the hypothesis that aging-associated increase on the
59flanking region of ERa could be associated to the decreased
expression of this receptor and could account to the imbalance on
ERb/ERa. Using methylation-sensitive qPCR we observed that
estrogen treatment is associated with increase on DNA methyla-
tion at ERa gene, an effect that could be involved into a negative
feedback to control ER expression. However, these studies showed
no aging-associated difference on DNA methylation on ERa gene.
Both SAMR and SAMP from either OVX or estrogen-treated
groups showed similar levels of DNA methylation at this site.
Therefore, changes of DNA methylation status on the gene
encoding ERa can explain estrogen-induced but not aging-
associated decrease of ERa expression.
Taking together our studies have established that aging has a
detrimental effect on estrogen-mediated regulation of NO and
O2
2 systems. An increase in the ratio between ERb and ERa in
older females is associated to the lack of the protective effects of
estrogen on NO production and with a reversal in its antioxidant
effect to a pro-oxidant profile. Although aged aortas display higher
levels of DNA methylation globally, this epigenetic modification
does not occur at the gene that encodes ERa and may be not
associated to the swap on ER expression. Changes in arterial
structure and function are the major vascular complication during
aging and have been largely associated with increased risk of
cardiovascular disease (such as atherosclerosis and hypertension) in
the elderly. Our result improves our knowledge into the field of
cardiovascular modulation by estrogens and establishes that aging
significantly affects the direct estrogen-mediated mechanisms of
vascular relaxation. Although the aging issue still needs to be
better addressed in both experimental and clinical studies, our
data demonstrate that estrogen has complex biologic effects and
may influence the risk of cardiovascular events and other
outcomes through multiple pathways. Therefore aging of a giving
organism should always be taken into account when the
pharmacological and physiological responses by estrogens are
determined.
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